Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Aug 26. pii: S0169-5002(19)30621-X. doi: 10.1016/j.lungcan.2019.08.020. [Epub ahead of print] No abstract available.

PMID:
31492438
2.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA.

Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.

PMID:
31319993
3.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Jul;133:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15.

PMID:
31200821
4.

Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.

Hann CL, Scherpereel A, Hellyer JA, Wakelee HA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:543-552. doi: 10.1200/EDBK_237847. Epub 2019 May 17.

PMID:
31099677
5.

Tumor Heterogeneity and Testing Discrepancy Confound ROS1 Detection in NSCLC.

Sun TY, Stehr H, Suarez CJ, Wakelee HA.

J Thorac Oncol. 2019 Jun;14(6):e111-e113. doi: 10.1016/j.jtho.2019.03.011. Epub 2019 Mar 23. No abstract available.

PMID:
30914313
6.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
7.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

Riess JW, Kong CS, West RB, Padda SK, Neal JW, Wakelee HA, Le QT.

Clin Lung Cancer. 2019 May;20(3):e356-e361. doi: 10.1016/j.cllc.2018.12.005. Epub 2018 Dec 21.

PMID:
30773448
8.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.

Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.

Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.

PMID:
30762593
9.

Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival.

Moghavem N, Wakelee HA, Nagpal S.

Ann Transl Med. 2018 Dec;6(Suppl 2):S118. doi: 10.21037/atm.2018.12.24. No abstract available.

10.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE.

Lung Cancer. 2019 Feb;128:74-90. doi: 10.1016/j.lungcan.2018.12.003. Epub 2018 Dec 6.

PMID:
30642457
11.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

PMID:
30550363
12.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV.

J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

13.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.

Myall NJ, Henry S, Wood D, Neal JW, Han SS, Padda SK, Wakelee HA.

Clin Lung Cancer. 2019 Mar;20(2):e208-e217. doi: 10.1016/j.cllc.2018.10.003. Epub 2018 Oct 23.

14.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.

Nguyen KH, Stehr H, Zhou L, Nguyen AH, Hiep PN, Van Cau N, Duy PC, Thorp R, Wakelee HA, Diehn M, Neal JW.

J Glob Oncol. 2018 Nov;4:1-9. doi: 10.1200/JGO.18.00086.

PMID:
30422746
15.

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.

Sun TY, Niu X, Chakraborty A, Neal JW, Wakelee HA.

J Thorac Oncol. 2019 Feb;14(2):e21-e24. doi: 10.1016/j.jtho.2018.08.2030. Epub 2018 Sep 11. No abstract available.

PMID:
30217491
16.

Caution Needed for Analyzing the Risks of Second Cancers.

Han SS, Plevritis SK, Wakelee HA.

J Thorac Oncol. 2018 Sep;13(9):e172-e173. doi: 10.1016/j.jtho.2018.04.018. No abstract available.

17.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW.

Oncologist. 2019 Jun;24(6):836-843. doi: 10.1634/theoncologist.2018-0264. Epub 2018 Aug 20.

PMID:
30126856
18.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Oct 1;29(10):2143. doi: 10.1093/annonc/mdy261. No abstract available.

PMID:
30060089
19.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.

Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic BI, Wakelee HA.

Cancer Chemother Pharmacol. 2018 Sep;82(3):541-550. doi: 10.1007/s00280-018-3646-0. Epub 2018 Jul 20.

PMID:
30030583
20.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

21.

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.

Tseng D, Padda SK, Wakelee HA.

J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008. No abstract available.

22.

Circulating tumor DNA testing in advanced non-small cell lung cancer.

Moding EJ, Diehn M, Wakelee HA.

Lung Cancer. 2018 May;119:42-47. doi: 10.1016/j.lungcan.2018.02.019. Epub 2018 Mar 2. Review.

PMID:
29656751
23.

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.

Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA.

Clin Lung Cancer. 2018 Sep;19(5):377-386. doi: 10.1016/j.cllc.2018.03.004. Epub 2018 Mar 17. Review.

24.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA.

J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.

25.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

26.

Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease.

Varlotto JM, Voland R, McKie K, Flickinger JC, DeCamp MM, Maddox D, Rava P, Fitzgerald TJ, Graeber G, Rassaei N, Oliveira P, Ali S, Belani C, Glanzman J, Wakelee HA, Patel M, Baima J, Zhang J, Walsh W.

Cancer Med. 2018 Apr;7(4):1211-1220. doi: 10.1002/cam4.1430. Epub 2018 Mar 13.

27.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ.

Lung Cancer. 2018 Mar;117:44-49. doi: 10.1016/j.lungcan.2018.01.010. Epub 2018 Feb 3.

28.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors.

Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA.

J Thorac Imaging. 2018 May;33(3):176-183. doi: 10.1097/RTI.0000000000000310.

29.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765.

30.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

31.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS.

J Thorac Oncol. 2018 Mar;13(3):436-446. doi: 10.1016/j.jtho.2017.11.118. Epub 2017 Nov 27.

32.

Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Niu X, Chuang JC, Berry GJ, Wakelee HA.

Curr Treat Options Oncol. 2017 Nov 16;18(12):71. doi: 10.1007/s11864-017-0513-x. Review.

PMID:
29143897
33.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.

34.

The J-ALEX trial-is frontline alectinib a new standard of care?

Zweig J, Wakelee HA.

J Thorac Dis. 2017 Aug;9(8):2242-2245. doi: 10.21037/jtd.2017.06.134. No abstract available.

35.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M.

Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.

36.

Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.

Bui N, Henry S, Wood D, Wakelee HA, Neal JW.

JCO Clin Cancer Inform. 2017;1. doi: 10.1200/CCI.16.00055. Epub 2017 Mar 13. No abstract available.

37.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.

Gensheimer MF, Hong JC, Chang-Halpenny C, Zhu H, Eclov NCW, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, Hara WY, Quon A, Maxim PG, Graves EE, Olson MR, Diehn M, Loo BW Jr.

Radiother Oncol. 2017 Nov;125(2):338-343. doi: 10.1016/j.radonc.2017.08.007. Epub 2017 Aug 19.

PMID:
28830717
38.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.

Choi CYH, Wakelee HA, Neal JW, Pinder-Schenck MC, Yu HM, Chang SD, Adler JR, Modlin LA, Harsh GR, Soltys SG.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):16-21. doi: 10.1016/j.ijrobp.2017.04.041. Epub 2017 May 6.

PMID:
28816142
39.

Risk Stratification for Second Primary Lung Cancer.

Han SS, Rivera GA, Tammemägi MC, Plevritis SK, Gomez SL, Cheng I, Wakelee HA.

J Clin Oncol. 2017 Sep 1;35(25):2893-2899. doi: 10.1200/JCO.2017.72.4203. Epub 2017 Jun 23.

40.

A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.

Harris JP, Patel MI, Loo BW, Wakelee HA, Diehn M.

Lung Cancer. 2017 Jun;108:173-182. doi: 10.1016/j.lungcan.2017.03.017. Epub 2017 Mar 29.

41.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

42.

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.

Baik CS, Myall NJ, Wakelee HA.

Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9. Review.

43.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

44.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN Jr.

Cancer Chemother Pharmacol. 2017 May;79(5):923-932. doi: 10.1007/s00280-017-3283-z. Epub 2017 Mar 28.

45.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW.

J Thorac Oncol. 2017 May;12(5):833-842. doi: 10.1016/j.jtho.2017.01.023. Epub 2017 Feb 4.

46.

Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

Neal JW, Wakelee HA.

J Clin Oncol. 2017 Apr 20;35(12):1269-1271. doi: 10.1200/JCO.2016.71.6084. Epub 2017 Feb 6. No abstract available.

PMID:
28165898
47.

Molecular profiling of single circulating tumor cells from lung cancer patients.

Park SM, Wong DJ, Ooi CC, Kurtz DM, Vermesh O, Aalipour A, Suh S, Pian KL, Chabon JJ, Lee SH, Jamali M, Say C, Carter JN, Lee LP, Kuschner WG, Schwartz EJ, Shrager JB, Neal JW, Wakelee HA, Diehn M, Nair VS, Wang SX, Gambhir SS.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8379-E8386. doi: 10.1073/pnas.1608461113. Epub 2016 Dec 12.

48.

Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'.

Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML.

Br J Cancer. 2017 Jan;116(3):e2. doi: 10.1038/bjc.2016.396. Epub 2016 Dec 6. No abstract available.

49.

Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.

Chuang JC, Liang Y, Wakelee HA.

Hematol Oncol Clin North Am. 2017 Feb;31(1):31-44. doi: 10.1016/j.hoc.2016.08.011. Review.

PMID:
27912832
50.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

Supplemental Content

Loading ...
Support Center